The U.S. analytical technology group is acquiring a majority stake in Dutch organ-on-a-chip specialist MIMETAS, bringing human tissue models into its broader portfolio of multiomics, spatial biology and preclinical imaging. The deal is another sign that organoids and microphysiological systems are moving from specialized research tools toward integrated platforms for drug discovery.
The emergence of agentic AI in lab automation
Background, Latest News, OpinionThere’s uncertainty and concern about whether AI will replace humans in workplaces. But Marco Ravot-Licheri, Head of Digital – Life Sciences Business at Tecan, told us that AI could increase laboratory productivity and make research more meaningful.
Swiss biotech Vaderis raises $152M to take first HHT-specific therapy into Phase 3
Latest NewsSwiss clinical-stage biotech Vaderis Therapeutics has raised $152 million in a Series B round to advance engasertib into Phase 3 for hereditary hemorrhagic telangiectasia (HHT). The financing, backed by a broad syndicate of specialist investors, gives the company a potentially decisive runway toward registration for a disease with no approved therapy.
Bruker Takes Majority Stake in dutch MIMETAS as Organoid Technologies Move Into the Mainstream
Latest NewsThe U.S. analytical technology group is acquiring a majority stake in Dutch organ-on-a-chip specialist MIMETAS, bringing human tissue models into its broader portfolio of multiomics, spatial biology and preclinical imaging. The deal is another sign that organoids and microphysiological systems are moving from specialized research tools toward integrated platforms for drug discovery.
Swedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3
Latest NewsSwedish rare-disease specialist Sobi is paying $75 million upfront for global commercial rights to Innate Pharma’s lacutamab, a first-in-class antibody targeting KIR3DL2 in cutaneous T-cell lymphoma. The deal gives Innate funding and a commercial partner for its next clinical step, while adding a late-stage oncology asset to Sobi’s rare-disease portfolio.
Clinical Development Expert has started
AppointmentsLondon-based EpilepsyGTx has appointed Dr Teresa Nunes as Chief Medical Officer (CMO) to support the continued development of the company’s gene therapy program, including its progression toward clinical development.
Actimed retrieves ALS drug after Faraday collapse
Latest NewsUK biotech Actimed Therapeutics has regained global rights to S-oxprenolol from the now-defunct Faraday Pharmaceuticals, giving it control of the experimental muscle-wasting drug across cancer cachexia, amyotrophic lateral sclerosis (ALS) and other potential indications.
Mironid lands $46M Series B to take kidney drug into clinic
Latest NewsScottish biotech Mironid has raised $46 million (€40 million) in a Series B financing to advance MR-L45, its small-molecule candidate for autosomal dominant polycystic kidney disease (ADPKD) through clinical development.
Evexta pairs ex-Merck drug with Roche’s giredestrant
Latest NewsFrench biotech Evexta Bio will combine its rupitasertib with Roche’s giredestrant in a Phase 1b trial targeting second-line, ESR1-mutated advanced breast cancer.
AstraZeneca taps Pathos for breast cancer degrader
Latest NewsAstraZeneca has put Pathos AI in charge of the early clinical development of AZD4241, its preclinical ERα degrader for ER-positive, HER2-negative breast cancer, under a co-exclusive licensing agreement.
Ipsen quietly returns cancer drug IPN01194 to AGV Discovery
Latest NewsIpsen confirmed to European Biotechnology that it has stopped developing the Phase 1/2a ERK inhibitor IPN01194 and will return worldwide rights to French biotech AGV Discovery.